|
|
Reference
|
|
|
*** (1993) Effect of Ramipril on Mortality and Morbidity of Survivors of Acute Myocardial Infarction with Clinical Evidence of Heart Failure: The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet, 342: 821-828
|
|
 
|
Anker, S.D., Butler, J., Filippatos, G., et al. (2021) Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med, 385(16): 1451-1461
|
|
|
Banka, G., Heidenreich, P.A., Fonarow, G.C. (2013) Incremental Cost-Effectiveness of Guideline-Directed Medical Therapies for Heart Failure. J Am Coll Cardiol, 61(13): 1440-1446
|
|
|
Cleland, J.G.F., Bunting, K.V., Flather, M.D., et al. (2018) Beta-Blockers for Heart Failure with Reduced, Mid-range, and Preserved Ejection Fraction: an Individual Patient-Level Analysis of Double-blind Randomized Trials. Eur Heart J, 39(1): 26-35
|
|
|
Cohn, J.N., Tognoni, G., Valsartan Heart Failure Trial Investigators (2001) A Randomized Trial of the Angiotensinreceptor Blocker Valsartan in Chronic Heart Failure. N Engl J Med, 345: 1667-1675
|
|
|
Consensus Trial Study Group (1987) Effects of Enalapril on Mortality in Severe Congestive Heart Failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med, 316: 1429-1435
|
|
|
Dasbach, E.J., Rich, M.W., Segal, R., et al. (1999) The Cost-Effectiveness of Losartan versus Captopril in Patients with Symptomatic Heart Failure. Cardiology, 91(3): 189-194
|
|
|
Desai, A.S., Solomon, S.D., Shah, A.M., et al. (2019) Effect of Sacubitril-Valsartan Vs Enalapril on Aortic Stiffness in Patients with Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA, 322(11): 1077-1084
|
|
|
Garg, R., Yusuf, S. (1995) Overview of Randomized Trials of Angiotensin-converting Enzyme Inhibitors on Mortality and Morbidity in Patients with Heart Failure: Collaborative Group on ACE Inhibitor Trials. JAMA, 273(18): 1450-1456
|
|
|
Glick, H., Cook, J., Kinosian, B., et al. (1995) Costs and Effects of Enalapril Therapy in Patients with Symptomatic Heart Failure: An Economic Analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial. J Card Fail, 1(5): 371-380
|
|
|
Halliday, B.P., Wassall, R., Lota, A.S., et al. (2018) Withdrawal of Pharmacological Treatment for Heart Failure in Patients with Recovered Dilated Cardiomyopathy (TRED-HF): An Open-Label, Pilot, Randomised Trial. Lancet, 393(10166): 61-73
|
|
1
|
Heidenreich, P.A., Bozkurt, B., Aguilar, D., Allen, L.A., Byun, J.J., Colvin, M.M., et al. (2022) AHA/ACC/HFSA Guideline for the Management of Heart Failure. A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol, 79(17): e263-e421
|
|
|
Isaza, N., Calvachi, P., Raber, I., et al. (2021) Cost-Effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction. JAMA Netw Open, 4(7): e2114501
|
|
|
Køber, L., Torp-Pedersen, C., Carlsen, J.E., et al. (1995) A Clinical Trial of the Angiotensin-Converting-Enzyme Inhibitor Trandolapril in Patients with Left Ventricular Dysfunction after Myocardial Infarction: Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med, 333(25): 1670-1676
|
|
|
Konstam, M.A., Neaton, J.D., Dickstein, K., et al. (2009) Effects of High-Dose Versus Low-Dose Losartan on Clinical Outcomes in Patients with Heart Failure (HEAAL Study): A Randomised, Double-Blind Trial. Lancet, 374(9704): 1840-1848
|
|
|
Lund, L.H., Claggett, B., Liu, J., et al. (2018) Heart Failure with Midrange Ejection Fraction in CHARM: Characteristics, Outcomes and Effect of Candesartan Across the Entire Ejection Fraction Spectrum. Eur J Heart Fail, 20(8): 1230-1239
|
|
|
McDonagh, T.A., Metra, M., Adamo, M. (2021) Citation:2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: Developed by the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) With the Speci. Eur Heart J, 42(36): 3599-3726
|
|
|
Mcmurray, J.J., Packer, M., Desai, A.S., et al. (2014) Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med, 371(11): 993-1004
|
|
|
Mcmurray, J.J.V., Solomon, S.D., Inzucchi, S.E. (2019) Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med, 381(21): 1995-2008
|
|
|
Nilsson, B.B., Lunde, P., Grogaard, H.K., et al. (2018) Long-Term Results of High-Intensity Exercise-Based Cardiac Rehabilitation in Revascularized Patients for Symptomatic Coronary Artery Disease. Am J Cardiol, 121(1): 21-26
|
|
|
ONTARGET Investigators, Yusuf, S., Teo, K.K., et al. (2008) Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. N Engl J Med, 358(15): 1547-1559
|
|
|
Packer, M., Poole-Wilson, P.A., Armstrong, P.W., et al. (1999) Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure: ATLAS Study Group. Circulation, 100(23): 2312-2318
|
|
|
Packer, M., Anker, S.D., Butler, J., et al. (2020) Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med, 383(15): 1413-1424
|
|
|
Parizo, J.T., Goldhaber-Fiebert, J.D., Salomon, J.A., et al. (2021) Cost-Effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiol, 6(8): 926-935
|
|
|
Paul, S.D., Kuntz, K.M., Eagle, K.A., et al. (1994) Costs and Effectiveness of Angiotensin Converting Enzyme Inhibition in Patients With Congestive Heart Failure. Arch Intern Med, 154(10): 1143-1149
|
|
|
Pfeffer, M.A., Braunwald, E., Moyew, L.A., et al. (1992) Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction After Myocardial Infarction: Results of the Survival and Ventricular Enlargement Trial: The SAVE Investigators. N Engl J Med, 327: 669-677
|
|
|
Pfeffer, M.A., Mcmurray, J.J.V., Velazquez, E.J., et al. (2003) Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. N Engl J Med, 349: 1893-1906, [published correction appears in N Engl J Med. 2004; 350: 203-203
|
|
|
Pfeffer, M.A., Claggett, B., Assmann, S.F., et al. (2014) Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial. Circulation, 131(1): 34-42
|
|
|
Pitt, B., Pfeffer, M.A., Assmann, S.F., et al. (2014) Spironolactone for Heart Failure with Preserved Ejection Fraction. N Engl J Med, 370(15): 1383-1392
|
|
|
Reed, S.D., Friedman, J.Y., Velazquez, E.J., et al. (2004) Multinational Economic Evaluation of Valsartan in Patients with Chronic Heart Failure: Results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J, 148(1): 122-128
|
|
|
Shekelle, P., Morton, S., Atkinson, S., et al. (2003) Pharmacologic Management of Heart Failure and Left Ventricular Systolic Dysfunction: Effect in Female, Black, and Diabetic Patients, and Cost-Effectiveness. Evid Rep Technol Assess (Summ), 1-6
|
|
|
Solomon, S.D., Vaduganathan, M., Claggett, B.L., et al. (2019) Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. Circulation, 141(5): 352-361
|
|
|
Solomon, S.D., Mcmurray, J.J.V., Anand, I.S., et al. (2019) Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med, 381(17): 1609-1620
|
|
|
Solomon, S.D., Claggett, B., Desai, A.S., et al. (2016) Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Fail. Circ Heart Fail, 9(3): e002744
|
|
4
|
SOLVD Investigators (1991) Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure. N Engl J Med, 25: 293-302
|
|
|
SPRINT Research Group, Wright, J.T. J., Williamson, J.D., et al. (2009) A Randomized Trial of Intensive Versus Standard Blood-Pressure Control. N Engl J Med, 373(22): 2103-2116
|
|
|
Telmisartan Randomised Assessment Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf, S., Teo, K., et al. (2008) Effects of the Angiotensin-Receptor Blocker Telmisartan on Cardiovascular Events in High-Risk Patients Intolerant to Angiotensin-Converting Enzyme Inhibitors: A Randomised Controlled Trial. Lancet, 372(9644): 1174-1183
|
|
|
Thomopoulos, C., Parati, G., Zanchetti, A. (2016) Effects of Bloodpressure-Lowering Treatment in Hypertension: 9. Discontinuations for Adverse Events Attributed to Different Classes of Antihypertensive Drugs: Metaanalyses of Randomized Trials. J Hypertens, 34(10): 1921-1932
|
|
|
Tsevat, J., Duke, D., Goldman, L., et al. (1995) Cost-Effectiveness of Captopril Therapy After Myocardial Infarction. J Am Coll Cardiol, 26(4): 914-919
|
|
|
Tsuji, K., Sakata, Y., Nochioka, K., et al. (2017) Characterization of Heart Failure Patients with Mid-Range Left Ventricular Ejection Fraction: A Report from the CHART-2 Study. Eur J Heart Fail, 19(10): 1258-1269
|
|
|
Velazquez, E.J., Morrow, D.A., Devore, A.D., et al. (2019) Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med, 380(6): 539-548
|
|
|
Wachter, R., Senni, M., Belohlavek, J., et al. (2019) Initiation of Sacubitril/valsartan in Haemodynamically Stabilised Heart Failure Patients in Hospital or Early After Discharge: Primary Results of the Randomised TRANSITION Study. Eur J Heart Fail, 21: 998-1007
|
|
|
Wang, Y., Zhou, R., Lu, C., et al. (2019) Effects of the Angiotensin-Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta-Analysis. J Am Heart Assoc, 8: e012272
|
|
|
Williamson, J.D., Supiano, M.A., Applegate, W.B., et al. (2016) Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial. JAMA, 315(24): 2673-2682
|
|
|
Woodard-Grice, A.V., Lucisano, A.C., Byrd, J.B., et al. (2010) Sex-Dependent and Race-dependent Association of XPNPEP2 C-2399A Polymorphism with Angiotensin-Converting Enzyme Inhibitor-Associated Angioedema. Pharmacogenet Genomics, 20(9): 532-536
|
|
|
Yusuf, S., Pfeffer, M.A., Swedberg, K., et al. (2003) Effects of Candesartan in Patients with Chronic Heart Failure and Preserved Left-Ventricular Ejection Fraction: The CHARM-Preserved Trial. Lancet, 362(9386): 777-781
|
|
|
Zheng, S.L., Chan, F.T., Nabeebaccus, A.A., et al. (2018) Drug Treatment Effects on Outcomes in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis. Heart, 104(5): 407-415
|
|
|
|
|